News Breaks |
|
|
| October 14, 2012 |
| 12:19 EDT |  | MRK | Merck: Odanacatib significantly increased BMD after prior alendronate treatment
Merck announced results from a Phase II trial for odanacatib, an investigational cathepsin K (cat-K) inhibitor in development for the treatment of osteoporosis in post-menopausal women. The results were presented today at the 34th Annual Meeting of the American Society for Bone and Mineral Research. In the study, treatment with odanacatib (compared to placebo) significantly increased Bone Mineral Density, BMD, over a two-year period in post-menopausal osteoporotic women who previously had three or more years of treatment with alendronate. Patients were allowed to have been off alendronate therapy for up to three months immediately prior to enrollment in the study. |
|
|
News For MRK From The Last 14 Days Check below for free stories on MRK the last two weeks. |
|
|
| May 16, 2013 |
| 08:55 EDT |  | MRK | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
 Subscribe for More Information |
|
| May 14, 2013 |
| 17:39 EDT | | MRK | Moody's lowers Merck's guaranteed debt to A1 from Aa3; stable outlook
Moody's Investors Service lowered the long-term ratings of Merck by one notch, including the guaranteed senior unsecured rating to A1 from Aa3 and the non-guaranteed senior unsecured rating to A2 from A1. This action concludes a review for downgrade initiated on May 1, 2013. At the same time, Moody's affirmed Merck's Prime-1 commercial paper rating. The rating outlook is stable. |
|
| May 10, 2013 |
| 11:48 EDT |  | MRK | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| 06:53 EDT | | MRK | GlaxoSmithKline, Merck to discount cancer vaccine in poor nations, NY Times says
Subscribe for More Information |
|
| May 9, 2013 |
| 07:22 EDT | | MRK | Merck awarded significant portion of UNICEF HPV vaccine tender
Subscribe for More Information |
|
| May 8, 2013 |
| 08:32 EDT | | MRK | Merck says FDA accepts biologics license application for allergy tablet
Merck announced that the Biologics License Application for its investigational ragweed pollen sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration. The BLA for Merck’s investigational ragweed pollen sublingual allergy immunotherapy tablet is supported by five studies evaluating the efficacy and safety of the tablet in adults, 18 years of age or older, with ragweed induced allergic rhinitis. On March 27, Merck announced that the FDA had also accepted the BLA for its investigational Timothy grass pollen sublingual allergy immunotherapy tablet. Merck expects the FDA’s review for both to be completed in the first half of 2014. |
|
| May 6, 2013 |
| 08:53 EDT | | MRK | BofA/Merrill's major pharma analysts hold an analyst/industry conference call
Subscribe for More Information |
|
| 07:18 EDT | | MRK | American Congress of Obstetrics and Gynecology to hold annual meeting
Subscribe for More Information |
|
|
|
|
|
